^
Association details:
Biomarker:CD73 expression
Cancer:Colorectal Cancer
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

Excerpt:
Patients (238 total) with first-line metastatic colorectal cancer (mCRC) were randomized to FOLFOX or FOLFIRI chemotherapy ± cetuximab...HER3 and CD73 expression levels were identified as potential predictive markers of benefit from cetuximab.
Secondary therapy:
FOLFIRI; FOLFOX
DOI:
10.1158/1078-0432.CCR-14-2313